Navigation Links
Encorium Group Signs Approximately $2.0 Million of New Business Contracts
Date:4/27/2009

WAYNE, Pa., April 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced the signing of approximately $2.0 million of new business contracts, consisting of both new business contracts and repeat business to be conducted primarily in Europe. Revenue recognition will begin in the second quarter of 2009 on a proportional basis as services are performed on each project. The backlog of the company was approximately $31.0 million at April 15, 2009.

Dr. David Ginsberg, Encorium Group's Chief Executive Officer, stated, "The contracts represent a continuation of our success in the field of vaccines and oncology and we plan to continue to further develop our already significant expertise in the therapeutic arenas of vaccines (both preventive and therapeutic) as well as oncology."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermato
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
2. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
3. Encorium Reports Third Quarter 2008 Financial Results
4. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
5. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
6. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Disabled and other vulnerable groups more susceptible to terrorism fears
9. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
10. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... & Young LLP ("EY") that it was resigning effective September ... to the Company on September 15, 2014 and reported in ... PDL has issued the following statement in response to ... inquiries on the reason for the resignation of EY.  We ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2
... Owner of PHC Consulting) hasn't felt a down economy at all. ... in the medical industry (laboratory clinical and research, physician call points, ... for revenues and Peggy attributes that growth to a strong web ... ...
... PALO ALTO, Calif., June 25 Cell Biosciences, ... systems,to life science researchers, today announced three important ... named President and Chief Executive Officer. From 1998,through ... for Molecular,Devices Corporation where he helped build the ...
... U.S. Food and Drug,Administration (FDA) Advisory Committee ... the approval of tolvaptan, Otsuka Pharmaceutical,Development & ... hyponatremia., "Otsuka is pleased that the ... tolvaptan, an investigational selective,V2-vasopressin receptor antagonist," said ...
Cached Biology Technology:Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2Cell Biosciences Announces New Leadership 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2
(Date:9/17/2014)... BELLINGHAM, Washington, USA -- "Nature has developed, very cleverly, ... we desire in optical design," said Joseph Shaw, director ... "As we explore surfaces and structures at the nanoscale, ... presented in San Diego in August during a conference ... by Shaw and Rongguang Liang of the University of ...
(Date:9/17/2014)... (Hospital del Mar Medical Research Institute) and at the ... study in eLife showing that RNA called ... of new proteins, some of which could have important ... from the instructions found in an RNA molecule. However, ... information for the synthesis of proteins, meaning it is ...
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Parts of genome without a known function may play a key role in the birth of new proteins 2Abnormal properties of cancer protein revealed in fly eyes 2
... Farmers who don,t rely on or want to minimize the ... battle against aggressive perennial weeds. In ongoing research at the ... be a worthy contender as a summer smother crop. ... The Sudangrass creates shade so photosynthesis cannot occur in the ...
... WEST LAFAYETTE, Ind. - Wheat plants found to ... in reinforcements to build up rigid defenses. Christie ... Agriculture,s Agricultural Research Service and a Purdue University associate ... by Hessian fly larvae increased production of surface waxes ...
... Bringing the power of synchrotron light to Minnesota,s ... of a Memorandum of Agreement (MOA) signed today between ... synchrotron facility, the Canadian Light Source (CLS). ... and product outcomes while improving operating efficiency for both ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3Resistant wheat rebuilds cell walls when attacked by Hessian flies 2BioBusiness Alliance, Canadian Light Source Synchrotron sign agreement 2
... HEXALIGHT robot is based on PI's experience ... more than a decade. PI Hexapods were ... and antenna adjustments over wide ranges in ... degrees of freedom with 3 m minimum ...
... length insert sequencing service for large insert ... Agencourt utilizes unique library construction techniques ... are several features that allow Agencourt to ... turnaround including our patented magnetic bead-based SPRI ...
... The Guava EasyCyte system is the first ... with built-in 96-well microplate sampling (with tube ... cells and compounds quickly and easily, without ... having the carryover issues found with other ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
Biology Products: